biostudies-literatureWapnir ILNCI NIH HHS1073-1079https://www.ebi.ac.uk/biostudies/studies/S-EPMC5891132biostudies-literatureUnknown36(11)Purpose Isolated locoregional recurrence (ILRR) predicts a high risk of developing breast cancer distant metastases and death. The Chemotherapy as Adjuvant for LOcally Recurrent breast cancer (CALOR) trial investigated the effectiveness of chemotherapy (CT) after local therapy for ILRR. A report at 5 years of median follow-up showed significant benefit of CT for estrogen receptor (ER)-negative ILRR, but additional follow-up was required in ER-positive ILRR. Patients and Methods CALOR was an open-label, randomized trial for patients with completely excised ILRR after unilateral breast cancer. Eligible patients were randomly assigned to receive CT or no CT and stratified by prior CT, hormone receptor status, and location of ILRR. Patients with hormone receptor-positive ILRR received adjuvantJournal of clinical oncology : official journal of the American Society of Clinical OncologyEfficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.PMC5891132UG1 CA189867U10 CA180868U10 CA180822Gelber RDNRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' GroupBreast International GroupPrice KNWapnir ILAnderson SJRimawi MFLang IPaterson AHGBaena-Canada JMThurlimann BAebi SMamounas EPRobidoux ARastogi PMartin MCoates ASGeyer CEGelber SRegan MMNortier JWRWolmark NInternational Breast Cancer Study GroupfalseEfficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.Purpose Isolated locoregional recurrence (ILRR) predicts a high risk of developing breast cancer distant metastases and death. The Chemotherapy as Adjuvant for LOcally Recurrent breast cancer (CALOR) trial investigated the effectiveness of chemotherapy (CT) after local therapy for ILRR. A report at 5 years of median follow-up showed significant benefit of CT for estrogen receptor (ER)-negative ILRR, but additional follow-up was required in ER-positive ILRR. Patients and Methods CALOR was an open-label, randomized trial for patients with completely excised ILRR after unilateral breast cancer. Eligible patients were randomly assigned to receive CT or no CT and stratified by prior CT, hormone receptor status, and location of ILRR. Patients with hormone receptor-positive ILRR received adjuvant2018-01-01T00:00:00Z2018 Apr2025-06-01T03:45:49.233Z2019-10-28T11:16:12ZS-EPMC58911322944365310.1200/jco.2017.76.571910.1200/JCO.2017.76.5719